These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 8611431)

  • 1. Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro.
    Siim BG; van Zijl PL; Brown JM
    Br J Cancer; 1996 Apr; 73(8):952-60. PubMed ID: 8611431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine.
    Olive PL
    Br J Cancer; 1995 Mar; 71(3):529-36. PubMed ID: 7880735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia.
    Siim BG; Menke DR; Dorie MJ; Brown JM
    Cancer Res; 1997 Jul; 57(14):2922-8. PubMed ID: 9230202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of the comet assay to detect hypoxic cells in murine tumours and normal tissues exposed to bioreductive drugs.
    Olive PL
    Acta Oncol; 1995; 34(3):301-5. PubMed ID: 7779413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SR 4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures.
    Biedermann KA; Wang J; Graham RP; Brown JM
    Br J Cancer; 1991 Mar; 63(3):358-62. PubMed ID: 2003976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the comet assay to identify cells sensitive to tirapazamine in multicell spheroids and tumors in mice.
    Olive PL; Vikse CM; Banath JP
    Cancer Res; 1996 Oct; 56(19):4460-3. PubMed ID: 8813141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual action of tirapazamine in the induction of DNA strand breaks.
    Jones GD; Weinfeld M
    Cancer Res; 1996 Apr; 56(7):1584-90. PubMed ID: 8603406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
    Siim BG; Pruijn FB; Sturman JR; Hogg A; Hay MP; Brown JM; Wilson WR
    Cancer Res; 2004 Jan; 64(2):736-42. PubMed ID: 14744792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reaction of the hypoxia-selective antitumor agent tirapazamine with a C1'-radical in single-stranded and double-stranded DNA: the drug and its metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA damage reactions.
    Hwang JT; Greenberg MM; Fuchs T; Gates KS
    Biochemistry; 1999 Oct; 38(43):14248-55. PubMed ID: 10571998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.
    Shibata T; Shibamoto Y; Sasai K; Oya N; Murata R; Takagi T; Hiraoka M; Takahashi M; Abe M
    Br J Cancer Suppl; 1996 Jul; 27():S61-4. PubMed ID: 8763848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxic sensitizer and cytotoxin for head and neck cancer.
    Lee DJ; Moini M; Giuliano J; Westra WH
    Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase.
    Fitzsimmons SA; Lewis AD; Riley RJ; Workman P
    Carcinogenesis; 1994 Aug; 15(8):1503-10. PubMed ID: 8055626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine.
    Dorie MJ; Kovacs MS; Gabalski EC; Adam M; Le QT; Bloch DA; Pinto HA; Terris DJ; Brown JM
    Neoplasia; 1999 Nov; 1(5):461-7. PubMed ID: 10933062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model.
    Kyle AH; Minchinton AI
    Cancer Chemother Pharmacol; 1999; 43(3):213-20. PubMed ID: 9923551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting.
    Delahoussaye YM; Hay MP; Pruijn FB; Denny WA; Brown JM
    Biochem Pharmacol; 2003 Jun; 65(11):1807-15. PubMed ID: 12781332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).
    Patterson AV; Barham HM; Chinje EC; Adams GE; Harris AL; Stratford IJ
    Br J Cancer; 1995 Nov; 72(5):1144-50. PubMed ID: 7577460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of the cytotoxicity of SR 4233 to normal and malignant tissues by hypoxic breathing.
    Minchinton AI; Brown JM
    Br J Cancer; 1992 Dec; 66(6):1053-8. PubMed ID: 1457345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre- and post-irradiation radiosensitization by SR 4233.
    Zeman EM; Brown JM
    Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):967-71. PubMed ID: 2703404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity.
    Elwell JH; Siim BG; Evans JW; Brown JM
    Biochem Pharmacol; 1997 Jul; 54(2):249-57. PubMed ID: 9271329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.
    Hay MP; Pruijn FB; Gamage SA; Liyanage HD; Kovacs MS; Patterson AV; Wilson WR; Brown JM; Denny WA
    J Med Chem; 2004 Jan; 47(2):475-88. PubMed ID: 14711317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.